

Significant support from shareholders for Rights Issue

Melbourne, Australia – 18 December 2018: dorsaVi Limited (**dorsaVi**) is pleased to advise that it has received valid acceptances under the 1 for 3 non-renounceable pro rata rights offer (**Offer**) announced on 21 November 2018 for a total (including applications received for additional shares under the shortfall facility and via the underwriting) of 36,010,620 new ordinary shares in dorsaVi raising approximately \$2.1 million before costs and expenses.

Whilst this leaves a shortfall of 19,704,036 shares (\$1,142,834) that have not been subscribed for under the Offer, dorsaVi is pleased with the support it has received from its shareholders in difficult market conditions. dorsaVi intends to use the funds raised to continue its successful push into the United States market and for working capital purposes.

dorsaVi would like to acknowledge that entitlements under the Offer were taken up by over 170 eligible shareholders including major shareholders, Starfish Technology Fund II Nominees A Pty Ltd and Starfish Technology Fund II Nominees B Pty Ltd which each subscribed for their full entitlements under the Offer.

Starfish Technology Fund II A Nominees Pty Ltd and Starfish Technology Fund II Nominees B Pty Ltd, each also agreed to subscribe for 6,896,552 of the shortfall shares (**Underwritten Shares**), pursuant to the underwriting arrangements described in the Offer statement. dorsaVi confirms that it does not intend to place any more shortfall shares.

The issue of all of the shares subscribed for under the Offer (including the Underwritten Shares) is expected to take place on Friday 21 December 2018 with trading of these shares on a normal settlement basis on ASX expected on Monday 24 December 2018.

ENDS

For more information about dorsaVi or to arrange an interview, please contact:

MEDIA
Megan Connell
dorsaVi
0416 116 526
mconnell@dorsavi.com

INVESTOR
Arthur Chan
WE Buchan
0404 369 388
arthurc@we-buchan.com

About dorsaVi

dorsaVi (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in elite sports, occupational health and safety and clinical applications. dorsaVi believes its wearable sensor technology enables – for the first time – many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours.



Our technology has applications across three sectors:

- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions - ViMove, ViMove2 and Professional Suite – which provide objective assessment, monitoring outside the clinic and immediate biofeedback. dorsaVi is currently used by medical and physiotherapy practices globally.
- **Elite Sports:** ViPerform is allowing coaches and medical teams managing elite athletes and teams to screen athletes and provide objective evidence for decisions on return to play, measure biomechanics and provide immediate biofeedback out on the field, tailor and track training programs and optimise technique and peak performance. ViPerform is being used in the US by the National Basketball Association (NBA), the Major Soccer League (MLS) and the National Football League (NFL), by the AFL and NRL clubs, Cricket Australia, and the Australian Institute of Sport (AIS) in Australia, and by Barclays Premier League (EPL) clubs, England and Wales Cricket Board and the Board of Control for Cricket in India as well as various Olympic teams and athletes internationally.
- **OHS:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to workplace design, equipment or methods based on objective evidence. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor), Crown and BHP Billiton.

Further information is available at www.dorsavi.com.